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Abstract Updated international guidelines published in
2006 have broadened the scope for the use of granulocyte
colony-stimulating factor (G-CSF) in supporting delivery of
myelosuppressive chemotherapy. G-CSF prophylaxis is
now recommended when the overall risk of febrile
neutropenia (FN) due to regimen and individual patient
factors is ≥20%, for supporting dose-dense and dose-
intense chemotherapy and to help maintain dose density
where dose reductions have been shown to compromise
outcomes. Indeed, there is now a large body of evidence for
the efficacy of G-CSFs in supporting dose-dense chemo-
therapy. Predictive tools that can help target those patients
who are most at risk of FN are now becoming available.
Recent analyses have shown that, by reducing the risk of
FN and chemotherapy dose delays and reductions, G-CSF
prophylaxis can potentially enhance survival benefits in
patients receiving chemotherapy in curative settings. Accu-
mulating data from ‘real-world’ clinical practice settings
indicate that patients often receive abbreviated courses of
daily G-CSF and consequently obtain a reduced level
of FN protection. A single dose of PEGylated G-CSF
(pegfilgrastim) may provide a more effective, as well as a
more convenient, alternative to daily G-CSF. Prospective
studies are needed to validate the importance of delivering
the full dose intensity of standard chemotherapy regimens,
with G-CSF support where appropriate, across a range of
settings. These studies should also incorporate prospective
evaluation of risk stratification for neutropenia and its
complications.
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Introduction
Neutropenia is a major dose-limiting toxicity of myelosup-
pressive chemotherapy that predisposes patients to serious
infections. Febrile neutropenia (FN), generally defined as
fever (single oral temperature ≥38.3°C or ≥38.0°C for >1 h)
with grade 3/4 neutropenia (absolute neutrophil count
[ANC] <1.0 or <0.5×10
9/l), is associated with substantial
morbidity, escalation of costs and mortality risk [1–5].
Severe neutropenia and FN episodes are also major drivers
of chemotherapy dose delays and reductions [6–8], which
have been shown to compromise survival outcomes in
various curative settings [7, 9–13].
Prophylaxis with recombinant granulocyte colony-
stimulating factors (G-CSFs) reduces the severity and
duration of chemotherapy-induced neutropenia and the
consequent risk of FN [14, 15]a n di sp l a y i n ga n
increasingly broad role in supporting the delivery of
myelosuppressive chemotherapy [16–18].
The aim of this article is to review recent developments
in the use of G-CSFs in this setting. A literature search was
conducted using the search terms “granulocyte colony-
stimulating factor”, “leukaemia”, “lymphoma” and “solid
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DOI 10.1007/s00520-010-0816-ytumours”. Additional studies were identified by hand-
searching reference lists of retrieved papers. Conference
websites were searched for recent reports (2006 onwards)
not covered by published literature, using the search terms
“G-CSF”, “granulocyte colony-stimulating factor”, “neu-
tropenia”, “filgrastim”, “lenograstim” and “pegfilgrastim”.
Who should receive G-CSFs?
Official guidelines from Europe and the USA now agree
that primary G-CSF prophylaxis should be given when
the overall risk of FN due to regimen and patient factors
is ≥20% [16–20]. Prior to 2006, primary G-CSF prophy-
laxis was recommended for chemotherapy regimens
associated with a relatively high FN risk of 40% [21].
However, data showed that clinical benefit was obtained
a tam u c hl o w e rt h r e s h o l do fr i s k[ 22, 23], and the
importance of individual patient risk factors was also
recognised [16, 17].
Regimens with an overall risk of FN of ≥20% include
anthracycline/taxane regimens that are used for treatment of
breast cancer, cyclophosphamide, doxorubicin, vincristine,
prednisone (CHOP)-like regimens used for non-Hodgkin’s
lymphoma (NHL) [16, 18] and the docetaxel, cisplatin and
5-fluorouracil (DCF/TPF) regimen used for gastric [24] and
head and neck [25, 26] cancer.
Immunomodulatory derivatives of thalidomide such
as lenalidomide have shown promise for the treatment
of myeloma [27, 28]. These agents appear to induce
neutropenia by transiently blocking the maturation of
granulocytes, rather than via stem cell toxicity, suggesting
that this might be prevented by G-CSF administration
[29]. Further work is required to define the risk of FN with
these agents.
For regimens that are associated with a 10–20% risk of
FN, individual patient factors must also be considered when
determining the need for G-CSF support (Fig. 1). There is
high-level evidence for older age, advanced-disease stage
and FN occurrence in a first or previous chemotherapy
cycle as risk factors for FN [16]. Other factors that have
been reported to increase risk include the presence of
comorbidities and poor performance/nutritional status [16–
18]. As age >65 years is consistently shown to be
associated with increased FN risk, G-CSF prophylaxis
should be considered for supporting chemotherapy delivery
in all elderly patients receiving myelotoxic chemotherapy
[30].
Historically, it was common practice to reduce the
chemotherapy dose instead of administering G-CSF in at-
risk patients, but this strategy risks obtaining suboptimal
results. Rather, G-CSF use should be guided by the intent
of treatment (i.e., whether curative or for prolonging
survival as opposed to palliative). If reduction in chemo-
therapy dose intensity or density is associated with poor
prognosis or where dose-dense or dose-intense chemother-
apy regimens have survival benefits, G-CSF prophylaxis
should be used. Where this is not crucial, use of a less
myelosuppressive chemotherapy regimen or dose/schedule
modification can be considered [16].
G-CSF to support chemotherapy: new data
Anthracycline/taxane regimens, particularly doxorubicin-
containing regimens, have become a standard of care in
breast cancer. Docetaxel, doxorubicin and cyclophospha-
mide (TAC) is a combination regimen that has high
efficacy in the adjuvant setting, reducing the risk of
death by 30% compared to fluorouracil, doxorubicin and
cyclophosphamide (FAC) [31]. While TAC is associated
with a relatively high risk of FN (>20%) and other
toxicities, delivery is feasible with effective growth factor
support [32, 33]. As well as reducing the risk of FN,
G-CSF prophylaxis has also be e nr e p o r t e dt oa t t e n u a t e
non-haematological toxicities such as aesthenia/anorexia,
stomatitis/mucositis and diarrhoea in TAC recipients [32,
33]. It is unknown whether this is a direct protective effect
or related to decreased cytokine release via the reduced
risk of infection.
Elderly patients have often not been considered as
candidates for full-dose aggressive chemotherapy, but there
is a growing body of evidence to show that, with adequate
G-CSF support, delivery of myelosuppressive chemothera-
py [34–37], including taxane-containing (neo)adjuvant
regimens [36, 37] and dose-dense CHOP (discussed in a
later section), is feasible in this population.
Recent prospective data from a large community-
based study have confirmed previous observations that
FN is most common in the first cycle of chemotherapy
[38], and this underlines the need to start G-CSF from the
first cycle in appropriate patients. Prophylactic use of G-
CSF (pegfilgrastim) from cycle 1 was shown to reduce the
incidence of FN by approximately 60% compared with
reactive use (initiated after cycle 1 at the physician’s
discretion) in elderly patients (aged ≥65 years; n=852)
receiving a range of mild to moderately myelosuppressive
chemotherapy regimens for solid tumours (lung, breast or
ovarian cancer) or NHL [35]. Among those with solid
tumours, FN occurred in 10% (95% confidence interval
[CI] 7–14%) of the reactive-use group versus 4% (95% CI
2–6%) of the pegfilgrastim primary prophylaxis group (p=
0.001). Among NHL patients, FN occurred in 37% (95%
CI 26–49%) of the reactive-use versus 15% (95% CI 8–
25%) of the pegfilgrastim primary prophylaxis group
(p=0.004).
530 Support Care Cancer (2010) 18:529–541Development of risk models
A number of groups have been developing predictive
models to identify patients at increased risk of severe
myelosuppression, low dose intensity and/or FN during
chemotherapy for breast cancer [8, 39–42], NHL [8, 43, 44]
or various cancer types [45–47]. The models are based on
traditional risk factors such as age, gender, bodyweight and
performance status, as well as disease type and stage,
haematology/clinical chemistry, chemotherapy, whether G-
CSF was given and a previous history of FN (Table 1). A
number of these have been validated retrospectively using
existing patient datasets [43, 46].
Jenkins et al. demonstrated that patients receiving
adjuvant 5-fluorouracil, epirubicin, cyclophosphamide
(FEC) chemotherapy for breast cancer could be divided
into five risk groups, in which the risk for neutropenic
events ranged from 18% to 52%, the risk of receiving
suboptimal (<85%) chemotherapy dose intensity from 9%
to 36% and the risk of FN from 4% to 21%, based only on
their pretreatment absolute neutrophil and lymphocyte
counts [40].
G-CSF USE 
NOT
INDICATED
PROPHYLACTIC 
G-CSF
RECOMMENDED
FN risk  20% FN risk 10%–20% FN risk <10%
Overall FN risk  20% Overall FN risk <20%
STEP 1: 
Assess FN risk for the planned chemotherapy regimen
Haemoglobin <12 g/dLa
Poor nutritional status a,b
Combined 
chemoradiotherapyb
Previous episode of FNa,b
Open wounds or 
active infectionsb
Age  65 yearsa,b
Poor performance status a,b
Advanced diseasea,b
Serious co-morbiditiesb
Cytopenias due to tumour 
bone marrow involvementb
Female gendera
STEP 2: Assess factors that may increase 
the risk of FN
Fig. 1 Algorithm for determining whether granulocyte colony-
stimulating factor (G-CSF) prophylaxis is indicated in patients
undergoing chemotherapy (represents a combined interpretation of
the 2006 G-CSF guidelines of the European Organisation for Research
and Treatment of Cancer and the American Society of Clinical
Oncology [16, 17]). FN febrile neutropenia. Adapted from (a) Aapro
et al. [16], with permission from Elsevier. Incorporating data from (b)
Smith TJ et al. [17]
Table 1 Risk models for febrile neutropenia (FN) or severe haemotoxicity in patients receiving myelosuppressive chemotherapy
Dranitsaris et al. [39] Pettengell et al. [44] Ziepert et al. [43] Lyman et al. [46]
Regimen/disease Doxorubicin or
liposomal doxorubicin/
metastatic breast cancer
Various/NHL CHOP-like regimens/
NHL
Various
Risk assessed
by model
Neutropenic
complications
a
FN Anaemia; leucocytopenia;
thrombocytopenia
Neutropenia
Basic characteristics Age ≥59 years;
performance status
Age; bodyweight Gender; bodyweight;
performance status
Older age
Disease
characteristics
Disease stage; bone
marrow involvement
Haematology/clinical
chemistry
Neutrophils ≤2×10
9/l
in previous cycle
Baseline albumin Baseline haemoglobin;
leucocytes;
thrombocytes;
GGT; LDH
WBC; abnormal hepatic
or renal function
Treatment factors Whether first cycle,
doxorubicin or
liposomal doxorubicin
Planned cyclophosphamide,
cytarabine, etoposide
dose; G-CSF use
Chemotherapy cycle
length; etoposide use;
vincristine dosage;
G-CSF use
Various chemotherapy
agents; prior chemotherapy;
immunosuppressive
agents; G-CSF use
History Previous chemotherapy;
recent infection
First cycle FN
CHOP cyclophosphamide, doxorubicin, vincristine, prednisone, GGT gamma glutamyltransferase, LDH lactate dehydrogenase, NHL non-
Hodgkin’s lymphoma
aAbsolute neutrophil count ≤1.5×10
9 cells/l, FN or neutropenia with a documented infection
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tool for predicting the grade of haematological toxicity
(leucopenia, thrombocytopenia and anaemia, but not specif-
ically neutropenia) in lymphoma patients treated with CHOP-
like therapies in clinical practice (www.toxcalculator.com). It
was calculated that use of these models, which again stratify
patients into five risk groups, could potentially spare
intensive prophylactic strategies in 10–38% or 16–38% of
patients, depending on whether cycle 1 data are available.
Pettengell et al. [44] found that their model had high
sensitivity (81%) and specificity (80%) for predicting cycle
1 FN in patients with NHL, with a 28% positive and 98%
negative predictive value.
Lyman et al. [46] developed a predictive model for
neutropenic events that they retrospectively validated, using
data from 4,458 patients treated for various cancers in
clinical practice. The model demonstrated good discrimi-
nation, predicting cycle 1 neutropenic events in 34% of
high-risk and 4% of low-risk patients, with a sensitivity and
specificity of 90% and 59%, respectively. G-CSF primary
prophylaxis was confirmed as a protective factor, and
almost two thirds of patients in the validation dataset who
were classified as high risk but did not receive primary G-
CSF prophylaxis subsequently received secondary G-CSF
prophylaxis in later cycles.
Once prospectively validated, such models will be a
valuable resource for helping to target G-CSF support.
Dose-dense/intense treatment
Shortening the time interval between chemotherapy cycles
from the conventional 3-week, to a 2-week, cycle—dose
densification—is thought to maximise tumour cell kill and
minimise regrowth between cycles [48, 49]. Moreover,
completion of chemotherapy within a shorter time frame
may allow patients to resume their normal activities sooner.
Earlier landmark studies with anthracycline/taxane regimens
in breast cancer [50], CHOP-like regimens in aggressive
lymphomas [51, 52] and doxorubicin/cyclophosphamide/
etoposide (ACE) chemotherapy in the small cell lung cancer
(SCLC) setting [53] showed that dose densification signif-
icantly improves response and survival outcomes.
G-CSF has been central to the paradigm of dose-dense
chemotherapy, as the short treatment cycle of 14 days
would not otherwise allow sufficient time for bone marrow
recovery between cycles. There is now a large body of new
evidence for the efficacy of G-CSF (filgrastim or pegfil-
grastim) in supporting delivery of dose-dense CHOP with
or without rituximab, at full dose, on time in patients with
NHL [54–57], including the elderly [54, 58, 59]. For
instance, younger patients with intermediate-risk aggressive
NHL were able to receive a dose-intense and dose-dense
CHOP regimen (cyclophosphamide 1,000 mg/m
2, doxoru-
bicin 70 mg/m
2, vincristine 2 mg and prednisone 100 mg×
5, delivered in 6×14-day cycles) with G-CSF support
(filgrastim) [55]. G-CSF (pegfilgrastim) also supported
delivery of dose-dense cyclophosphamide, doxorubicin,
etoposide, vincristine, bleomycin, procarbazine and predni-
sone at full dose, on time in patients with Hodgkin’s
lymphoma [60].
In the breast cancer setting, several recent reports have
documented the efficacy of pegfilgrastim in supporting
delivery of dose-dense anthracycline/taxane regimens,
including docetaxel followed by epirubicin/cyclophospha-
mide (T→EC) or the reverse sequence (EC→T) [61] and
fluorouracil, epirubicin, cyclophosphamide→docetaxel
(FEC→Doc) [62], as well as FEC alone [63]. Dose-dense
sequential doxorubicin plus cyclophosphamide followed by
paclitaxel (AC→T) was well tolerated when administered
with pegfilgrastim and additional red cell support (darbe-
poetin alfa) in patients with haemoglobin ≤12 g/dl, with
few chemotherapy dose reductions or episodes of FN (<2%
of patients) [64].
In patients with SCLC, full-dose, on-schedule, dose-
dense ACE chemotherapy was found to be feasible with
pegfilgrastim support [65].
Use of G-CSF has also allowed investigation of higher
chemotherapy dosages, but the benefits of dose escalation
alone are presently unclear, suggesting that currently used
dosages may already be optimal in most settings, provided
that they can be delivered safely. For instance, significant
dose escalations of cyclophosphamide, doxorubicin, vin-
cristine, prednisone and etoposide (CHOEP) were possible
with G-CSF support (filgrastim or lenograstim) in young
patients with lymphoma [66], but this strategy did not
enhance clinical benefits compared with standard CHOEP-
21 [67].
Impact of G-CSF on chemotherapy delivery
and survival outcomes
Recent data from a large US survey (41,779 patients with
FN treated at 115 medical centres) have highlighted the
mortality risk associated with FN. Overall, in-hospital
mortality was 9.5% and increased with the number of
comorbidities: 2.6% in those without any major comorbid-
ity, 10.3% in those with one major comorbidity and >21%
in those with more than one major comorbidity [3].
There are now much data to show that reduced
chemotherapy dose intensity due to delays and dose
reductions can potentially compromise survival outcomes
in patients receiving curative treatment [7, 9–13, 68]. Even
moderate reductions can negatively impact survival. For
instance, in NHL patients treated with CHOP-like chemo-
therapy (n=210), failure to achieve a relative dose intensity
532 Support Care Cancer (2010) 18:529–541(RDI; the ratio of actual dose to planned dose of
chemotherapy over the same time interval) of >90%
resulted in significantly shorter mean overall survival
(2.24 vs. 5.38 years; p=0.002) [7].
The prospective Impact of Neutropenia in Chemotherapy-
European observational study in breast cancer (n=444) and
lymphoma (n=305) patients undergoing chemotherapy
found that first-cycle FN, age ≥65 years and Eastern
Cooperative Oncology Group (ECOG) performance score
>1 were associated with low RDI in both groups of patients,
with G-CSF primary prophylaxis protecting against low RDI
in the lymphoma patients [8]. A meta-analysis of ten studies
that reported RDI as an outcome found that average RDI in
patients treated for solid tumours or lymphoma ranged from
91.0% to 99.0% (mean 95.1%) in patients who received G-
CSF, compared with only 71.0 to 95.0% (mean 86.7%) in
those who did not [69].
There is now a growing body of evidence that improved
chemotherapy delivery and reduction in FN with G-CSF [8,
69] may translate into better survival outcomes. Three
meta-analyses of randomised studies comparing prophylac-
tic G-CSF or granulocyte-macrophage colony-stimulating
factor (GM-CSF) with placebo or no treatment have been
conducted recently [69–71].
A meta-analysis of 17 studies compared primary
prophylactic G-CSF (filgrastim, lenograstim or pegfilgras-
tim) with placebo or no treatment in 3,493 patients treated
for solid tumours or lymphoma. In addition to improving
RDI, G-CSF reduced the risk of infection-related mortality
by 45% (1.5% vs. 2.8%: relative risk [RR] 0.55, 95% CI
0.33–0.90; p=0.018) and early mortality (all-cause, during
chemotherapy) by 40% (3.4% vs. 5.7%: RR 0.60, 95% CI
0.43–0.83; p=0.002; Fig. 2). As the patient populations in
the studies included in this analysis tended to be relatively
young and fit, it is possible that greater benefit of G-CSF
might be seen in older populations [69].
However, a meta-analysis of 148 studies in a broad range
of settings, including adults and children with cancer or
undergoing stem cell transplantation, found prophylactic G-
CSF or GM-CSF to have little or no effect on early mortality
(7.6% vs. 8.0% of patients) or infection-related mortality
(3.1% vs. 3.8%) versus placebo/no treatment [70]. Neverthe-
less, G(M)-CSF did reduce the risk of documented infections
(median 38.9% vs. 43.1%; rate ratio 0.85, 95% CI 0.79–
0.92) and microbiologically documented infections (median
rate 23.5% vs. 28.6%; rate ratio 0.86, 95% CI 0.77–0.96)
[70]. Similarly, a recent Cochrane database review of 13
trials in patients treated for lymphoma (n=2,607) did not
find any benefit of G-CSF or GM-CSF on overall survival
(HR 0.97, 95% CI 0.87–1.09), freedom from treatment
failure (HR 1.11, 95% CI 0.91–1.35), complete response
(RR 1.03, 95% CI 0.95–1.10) or infection-related mortality
(RR 0.93, 95% CI 0.51–1.71) [71].
The reasons for the differences between results of these
three meta-analyses are not clear but probably relate to
differences in individual study methodology and endpoints,
as well as criteria for inclusion of studies. Both analyses
that failed to show an effect of CSFs on mortality endpoints
included studies that used GM-CSF (sargramostim or
molgramostim) [70, 71], whereas the meta-analysis that
demonstrated a survival benefit was restricted to studies of
G-CSF [69]. It is thought that GM-CSF may be less
effective than G-CSF in reducing FN and fever [72], and its
use has been discontinued in Europe. In the USA, GM-CSF
is not FDA-approved as an adjunct to standard myelosup-
pressive chemotherapy regimens in patients with solid
tumours and lymphoma and has limited off-label use in
this setting. Indeed, 61 of the 148 studies included in the
Sung analysis used GM-CSF [70]. This analysis included
transplant patients receiving high-dose chemotherapy, a
different scenario from use of CSFs to support standard-
dose chemotherapy. Moreover, only the Kuderer analysis
[69] was restricted to trials in which daily CSFs were to be
given continuously until neutrophil recovery.
Nevertheless, all three meta-analyses confirmed a sub-
stantial FN risk reduction in patients receiving G-CSF/GM-
CSF support [69–71]. For instance, Kuderer et al. found
that FN was reduced by 46% (22.4% vs. 39.5%: RR 0.54,
95% CI 0.43–0.67; p<0.001) [69].
Exploratory data from a prospective observational study
conducted at 115 US practices (n=4,458 patients) showed
that pegfilgrastim significantly improved survival endpoints
in patients with comorbidities who were receiving chemo-
therapy [73]. Of these patients, 41% were aged >65 years,
46% had ECOG performance score >1 and 38% had stage 4
disease. Patients receiving primary pegfilgrastim prophy-
laxis (n=620) had better progression-free survival than
those who did not, even after adjustment for other
significant covariates. This study was not randomised,
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Fig. 2 Efficacy of primary prophylactic granulocyte colony-
stimulating factor (G-CSF; pegfilgrastim, filgrastim or lenograstim)
versus placebo or no treatment in preventing febrile neutropenia (FN),
infection-related mortality (INF mortality) and early mortality (all-
cause, during chemotherapy) in 3,493 patients treated with chemo-
therapy for solid tumours or lymphoma. Results of a meta-analysis of
17 studies [69]
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consistent with the G-CSF meta-analysis [69].
Are the G-CSFs different?
The non-PEGylated G-CSFs, standard G-CSF (filgrastim)
and glycosylated G-CSF (lenograstim) appear to be broadly
comparable in efficacy [16]. However, a growing body of
evidence suggests that pegfilgrastim—a PEGylated formu-
lation of filgrastim with neutrophil-regulated pharmacokinet-
ics that is given as a single dose once per cycle [57, 74]—is
more effective than filgrastim. A meta-analysis of five
studies in a total of 617 patients treated for breast cancer or
lymphoma showed that a single dose of pegfilgrastim was
significantly more effective than 10–14 days of filgrastim in
reducing FN (RR 0.64, 95% CI 0.43–0.97) [75]. Data from
the larger meta-analysis by Kuderer et al. [69]a l s os u g g e s t
that pegfilgrastim was more effective than either lenograstim
or filgrastim, although it must be noted that the pegfilgrastim
data came from a single study (Fig. 3). These findings might
reflect the sustained stimulation of bone marrow by
pegfilgrastim throughout the period of neutropenia.
Moreover, the way that filgrastim is administered in real-
world clinical practice (and some clinical trials) may
compromise its efficacy. It should be given daily, until ANC
returns to the normal range; data from registrational trials
indicate that this requires approximately 9–14 injections per
chemotherapy cycle [14, 76]. However, it is common
practice to administer fewer doses than this and/or to start
treatment relatively late after chemotherapy [77–79]. Several
analyses have shown that, when used in this manner,
filgrastim may provide suboptimal protection against FN
[33, 78, 79]. For instance, the Gepartrio study evaluated four
different supportive regimens in consecutive cohorts of
patients (n=1,256 total) receiving adjuvant TAC for breast
cancer. FN occurred in 18% of patients who received an
abbreviated course of daily G-CSF administered from days 5
to 10. However, a single dose of pegfilgrastim on day 2
reduced the incidence of FN to 7%; if ciprofloxacin was also
incorporated into the prophylactic regimen, the risk was
reduced to 5% (Fig. 4)[ 33].
An integrated analysis of data from 2,282 breast cancer
patients compared pegfilgrastim primary prophylaxis with
current-practice neutropenia management (a: no G-CSF or b:
any G-CSF use other than protocol-specified pegfilgrastim
RR 0.08 (95% CI: 0.03-0.18) (P=0.000) Pegfilgrastim*
RR 0.62 (95% CI: 0.44-0.88) (P=0.007) Lenograstim
RR 0.61 (95% CI: 0.53-0.72) (P=0.000) Filgrastim
RR 0.36 (95% CI: 0.13-0.99) (P=0.047) Pegfilgrastim*
RR 0.84 (95% CI: 0.38-1.83) (P=0.657) Lenograstim
RR 0.60 (95% CI: 0.41-0.89) (P=0.010) Filgrastim
RR 0.20 (95% CI: 0.01-4.17) (P=0.300)
Pegfilgrastim*
RR 0.83 (95% CI: 0.26-2.68) (P=0.755)  Lenograstim
RR 0.53 (95% CI: 0.30-0.92) (P=0.024) Filgrastim
Relative Risk (95% CI)
0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5
c) Febrile Neutropenia
b) Early mortality
a) Infection-related mortality
Favours G-CSF Favours no G-CSF / placebo
*only 1 pegfilgrastim trial was identified
Fig. 3 Efficacy of different granulocyte colony-stimulating factors in
preventing infection-related mortality, early mortality and febrile
neutropenia in 3,493 patients treated with chemotherapy for solid
tumours or lymphoma. Forest plot of data from a meta-analysis of 17
randomised controlled studies comparing G-CSF primary prophylaxis
with placebo or no treatment [69]
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associated with a moderately high/high FN risk [80]. The
most common chemotherapy regimens were docetaxel or
taxane/anthracycline combinations. Usage of primary G-CSF
prophylaxis was low in the current-practice group: 75% of
these patients did not receive any G-CSF prophylaxis in the
first cycle. FN was markedly less frequent in the pegfil-
grastim group compared with the current-practice group (5%
versus 29%, adjusted for age, disease stage and study;
adjusted odds ratio [OR] 0.124, 95% CI 0.08–0.194; p<
0.0001). A subanalysis in elderly patients (n=285, aged
≥65 years) showed similar results: FN occurred in 6% (95%
CI 2–10%) of the pegfilgrastim group versus 24% (95% CI
16–32%) of the current-practice group, while dose reduc-
tions occurred in 15% versus 29% of patients [37].
A retrospective US survey [77] of patients (n=6,148)
treated in 99 community oncology practices for various
cancers also found that FN was more common in those who
received filgrastim (6.5%) than in those who received
pegfilgrastim (4.7%) [adjusted OR 1.41, 95% CI 1.02–1.96;
p=0.040]. However, whereas pegfilgrastim was adminis-
tered within approximately 2 days after chemotherapy,
filgrastim was started much later (mean >7 days and
>5 days after chemotherapy in first and subsequent cycles,
respectively), suggesting that filgrastim was used reactively
instead of proactively. A similar analysis found that in
community-based patients receiving various chemotherapy
regimens (total of 15,763 cycles), the risk of hospitalisation
was approximately 30% lower with pegfilgrastim support
than with daily G-CSF [81].
Alternative versions of many innovative biopharmaceut-
icals, including G-CSF [82], are being developed. These
“biosimilars” will not be identical to the corresponding
original products because of differing protein sources and
difficulties in replicating the complex proprietary manufac-
turing processes involved. While biosimilars may cost less,
it is possible that small differences in biochemical and
biophysical characteristics might translate into differences
in potency and immunogenic potential [83].
Tolerability issues
Bone pain
Bone or musculoskeletal pain is a characteristic adverse
event associated with G-CSF treatment. This is generally
mild to moderate and can be managed with standard
analgesics [84–86]. A large meta-analysis [69] found that
bone or musculoskeletal pain was reported in approximate-
ly 20% of patients who received G-CSFs compared with
approximately 10% of controls (RR 4.023, 95% CI 2.156–
7.52; p<0.0001). Arthralgia is also an adverse effect of
taxane chemotherapy [87], which is often administered with
G-CSF support. Filgrastim and pegfilgrastim were associ-
ated with similar incidences of bone pain in another large
analysis (RR 0.95, 95% CI 0.76–1.19) [75]. Although
administering a lower-than-recommended dose of G-CSF
(pegfilgrastim) was reported to be successful in reducing
bone pain [88], this strategy obviously risks achieving
suboptimal protection against FN [89], and it is at yet
unclear whether bone pain is dose-related.
Other short-term adverse events
A proportion of patients may experience leucocytosis
(white blood cell count >100×10
9/l) after receiving G-
CSFs [64, 84, 90]. At ANC recovery, pegfilgrastim
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Fig. 4 Comparison of febrile neutropenia and grade 4 neutropenia
incidence per patient and per cycle in patients receiving TAC
chemotherapy for early breast cancer, supported by different primary
prophylactic regimens: ciprofloxacin 500 mg orally twice daily on
days 5–14 (n=253 patients), daily granulocyte colony-stimulating
factor (G-CSF; filgrastim 5 µg/kg per day or lenograstim 150 µg/m
2
per day) on days 5–10 (n=374), pegfilgrastim (PEG) 6 mg on day 2
(n=303) or pegfilgrastim plus ciprofloxacin (PEG+CIP; n=314) [33].
*p<0.01, **p<0.001 versus CIP; †p<0.01, ††p<0.001 versus daily
G-CSF. Reprinted from von Minckwitz et al. [33]. By permission of
Oxford Journals/European Society for Medical Oncology
Support Care Cancer (2010) 18:529–541 535clearance increases, resulting in a rapid decrease in serum
concentrations. This resulted in less “overshoot” of ANC
post-nadir compared with daily filgrastim [91]. Pegfilgras-
tim concentrations are negligible by day 12 and therefore
unlikely to overstimulate neutrophil production [92].
G-CSFs can induce elevation of cancer antigen 15-3, a
circulating marker of secreted products of the polymorphic
MUC1 gene used for monitoring breast cancers, in breast
cancer patients [93–96]. Physicians should be aware of the
potential for this “false-positive” effect, which may occur
via an increase in neutrophil counts or induction of MUC1
antigen [95]. There is no evidence that this is due to tumour
stimulation.
Secondary malignancies
On the basis of retrospective data, it has been suggested that
G-CSF/GM-CSF use might lead to a small increase in the risk
of secondary malignancies. In patients treated with adjuvant
chemotherapy for breast cancer, acute myeloid leukaemia or
myelodysplastic syndrome (AML/MDS) occurred in 1.77%
of those who had received G-CSF or GM-CSF (n=906)
compared with 1.04% of those who had not (n=4,604; HR
2.14, 95% CI 1.12–4.08) [97]. However, as acknowledged
by the investigators, anthracyclines and cyclophosphamide
may increase the risk of second malignancies in a dose-
related manner [98–100]; administration of G-CSF may have
allowed higher chemotherapy doses to be delivered, thereby
confounding the analysis. Moreover, data from other studies,
including a very large observational study (n=64,715) [100],
have not indicated an increased risk of secondary AML/
MDS with G-CSF use [50, 100, 101].
A recent meta-analysis found that although intensified
chemotherapy with G-CSF support slightly increased the
risk of second malignancies compared with standard
chemotherapy without G-CSF, this was more than offset
by the survival benefits [102]. Thus, the overall risk/benefit
ratio continues to favour G-CSF use [103], as it facilitates
chemotherapy delivery and prevents life-threatening FN.
Clinical implications of new data
Guidelines published from 2006 onwards have broadened
the scope of G-CSF use for supporting chemotherapy
delivery. There is now a large body of evidence for the
efficacy of pegfilgrastim, as well as filgrastim, in support-
ing dose-dense chemotherapy and facilitating delivery of
the full dose on time. Importantly, recent data have
provided further (albeit indirect) evidence that appropriate
primary G-CSF prophylaxis can potentially confer survival
benefits in patients receiving chemotherapy in the curative
setting.
FN risk should be assessed on an individual patient
basis, taking into account the regimen, patient- and disease-
related factors and treatment intent. Predictive tools that
will help clinicians to identify which patients are most
likely to benefit from G-CSF prophylaxis are now starting
to become available, and these will allow more efficient
targeting of patients at high risk.
Several studies have documented the considerable cost
burden of FN in patients receiving chemotherapy [1, 3]. An
analysis in >40,000 US patients found that, on average, an
FN episode resulted in a median hospital stay of 6 days and
a median cost of $8,376, with 35% of patients being
hospitalised for at least 10 days [3]. Smaller studies from
various western European countries have provided esti-
mates of the average charge for FN-related hospitalisation
ranging from €2,619 in Spain to €4,931 in France [4, 104,
105]. These findings highlight the need to implement
official guidelines for preventing FN. A number of
economic analyses have indicated that the costs of G-
CSFs can be at least partially offset by reduction of FN and
its associated costs [106–108]. It should be noted that
results of cost-effectiveness studies are dependent on the
costs considered by each study, and such costs may differ
between countries.
It is important that G-CSFs are used according to
recommendations in order to gain the maximum benefit.
In real-world clinical practice settings, patients often
receive abbreviated courses of daily G-CSF treatment and
this can reduce the level of FN protection obtained. Use of
a single dose of pegfilgrastim per cycle in appropriate
patients assures the delivery of adequate CSF support,
providing a more convenient and potentially more effective
strategy for assisting neutrophil recovery.
Prospective studies are needed to validate the importance
of delivering the full dose intensity of standard chemother-
apy regimens, integrated with G-CSF support where
appropriate, across a range of tumour types. This will allow
better quantification of the impact of both chemotherapy
dose and supportive care in improving outcomes in cancer
patients. These studies should also incorporate prospective
evaluation of risk stratification for neutropenia and its
complications, so that the use of both chemotherapy and G-
CSFs can be optimised in the most cost-effective way.
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